The development of a dual anti-EGFR/anti-hCA IX (CTX+AZM) targeting nanoprobe is also reported, and its performance as a precision therapeutic tool against CRC is compared with that of each individual NANO3-anchored antigen. This evidence concerns the gene EGFR and colorectal carcinoma.